Skyclarys: First Approved Treatment for Friedreich’s Ataxia Offers Hope

For individuals living with Friedreich’s ataxia (FA), a rare and debilitating genetic disease, a new treatment called Skyclarys (omaveloxolone) represents a significant step forward. Approved by the U.S. Food and Drug Administration (FDA) in 2023, Skyclarys is the first and currently only approved medication specifically designed to address the underlying causes of FA. However, access to the drug remains a challenge for patients in some regions, including Ireland, where reimbursement decisions are still pending.

Understanding Friedreich’s Ataxia

Friedreich’s ataxia is an inherited degenerative disease that primarily affects the nervous system, causing progressive damage to the spinal cord, peripheral nerves and brain. The FDA describes the condition as characterized by impaired coordination, difficulty walking, changes in speech and swallowing, and a shortened lifespan. It typically develops in childhood or adolescence and worsens over time. The disease affects approximately one in every 50,000 people in the United States, making it the most common form of hereditary ataxia in the country.

How Skyclarys Works

Skyclarys (omaveloxolone) works by activating a protein called Nrf2, which plays a crucial role in protecting cells from oxidative stress and inflammation. Research suggests that activating Nrf2 can help slow the progression of FA by improving mitochondrial function and reducing cellular damage. Clinical trials have shown that Skyclarys can lead to improvements in speech, typing, texting, walking, and fatigue in some patients. Approximately 50% of patients report some improvement, while around 40% experience no noticeable progression of the disease for the first time. About 10% report no benefit.

Clinical Trial Results and Efficacy

The efficacy of Skyclarys was evaluated in a 48-week randomized, placebo-controlled, and double-blind study involving 103 individuals with Friedreich’s ataxia. The study, identified as NCT02255435, compared the change in modified Friedreich’s Ataxia Rating Scale (mFARS) scores between those receiving Skyclarys and those receiving a placebo. The mFARS assesses disease progression in areas such as swallowing, speech, limb coordination, and balance. Participants receiving Skyclarys demonstrated better performance on the mFARS compared to the placebo group.

Challenges to Access: The Irish Experience

Despite the promising results, access to Skyclarys remains a challenge for many patients. In Ireland, approximately 200 people live with Friedreich’s ataxia. Campaigners recently met with Minister for Health Jennifer Carroll MacNeill to advocate for the drug’s reimbursement. However, a report from the National Centre for Pharmaeconomics (NCPE) in December recommended against reimbursing the drug, leaving patients in a state of uncertainty. Emily Felix, a 28-year-old trainee solicitor with FA, highlights the urgency of the situation, stating that delays in treatment have real-life consequences and could impact her ability to benefit from potential future cures. Ms. Felix is experiencing rapidly deteriorating speech and mobility and has begun using a voice-banking app to preserve her voice.

Looking Ahead

The approval of Skyclarys marks a turning point in the treatment of Friedreich’s ataxia, offering hope to patients and families affected by this devastating disease. While challenges related to access and reimbursement persist, ongoing research and advocacy efforts are crucial to ensuring that all eligible individuals can benefit from this groundbreaking therapy. Further studies are underway to explore the long-term effects of Skyclarys and its potential benefits for younger patients.